Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain
- Status
- TERMINATED
- Phase
- PHASE2
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
- Status
- TERMINATED
- Phase
- PHASE2
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
- Status
- TERMINATED
- Phase
- PHASE1
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
- Status
- TERMINATED
- Phase
- PHASE2
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
- Status
- COMPLETED
- Phase
- NA
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
- Status
- COMPLETED
- Phase
- PHASE2
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2